ESMO 2014 Industry Satellite Symposium

MELANOMA

Should Immuno-Oncology be the foundational treatment strategy for all patients with melanoma?

Saturday 27 September 18.00–20.00
Cordoba Auditorium

Co-Chairs:

Axel Hauschild, Schleswig-Holstein, Germany Reinhard Dummer, Zürich, Switzerland

Agenda:

Refreshments 18.00–18.30	
Welcome and introduction	Axel Hauschild and Reinhard Dummer
Why do you need to involve the immune system?	Pedro Romero, Lausanne, Switzerland
Embedding Immuno-Oncology into everyday clinical practice	Axel Hauschild and Reinhard Dummer
Combining checkpoint inhibitors – maximizing the body's immune response to cancer?	John Kirkwood, Pittsburgh, USA
What about other Immuno-Oncology pathways?	Paolo Ascierto, Naples, Italy
Summary and close	Axel Hauschild and Reinhard Dummer



